**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. **Name and Address of Reporting Person**
   - Zaks Tal Zvi
   - C/O MODERNA, INC.
   - 200 TECHNOLOGY SQUARE
   - CAMBRIDGE MA 02139

2. **Issuer Name and Ticker or Trading Symbol**
   - Moderna, Inc. [ MRNA ]

3. **Date of Earliest Transaction (Month/Day/Year)**
   - 08/03/2020

4. **If Amendment, Date of Original Filed (Month/Day/Year)**
   - 08/03/2020

5. **Relationship of Reporting Person(s) to Issuer**
   - Director
   - Chief Medical Officer
   - 10% Owner

6. **Individual or Joint/Group Filing**
   - Form filed by One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Securities Acquired/Disposed</th>
<th>Date</th>
<th>Transaction</th>
<th>Code</th>
<th>Number</th>
<th>Price</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/03/2020</td>
<td>M(1)</td>
<td>10,000</td>
<td>$20.93</td>
<td>0,000</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/03/2020</td>
<td>M(1)</td>
<td>10,000</td>
<td>$19.15</td>
<td>0,000</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/03/2020</td>
<td>S(1)</td>
<td>20,000</td>
<td>$74.89</td>
<td>0,000</td>
<td>D</td>
</tr>
</tbody>
</table>

---

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Derivative Security</th>
<th>Conversion or Exercise Price</th>
<th>Date</th>
<th>Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option</td>
<td>$20.93</td>
<td>08/03/2020</td>
<td>03/08/2020</td>
<td>Common Stock</td>
<td>10,000</td>
<td>$289,195</td>
</tr>
<tr>
<td>Stock Option</td>
<td>$19.15</td>
<td>08/03/2020</td>
<td>(2)</td>
<td>Common Stock</td>
<td>10,000</td>
<td>$194,790</td>
</tr>
</tbody>
</table>

**Explanation of Responses:**
1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
2. This option is fully vested and exercisable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Signature of Reporting Person**

Date: 08/04/2020